Drug Profile

GMI 1359

Alternative Names: GMI-1359

Latest Information Update: 17 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlycoMimetics
Developer Crescent Biopharma
Class Antineoplastics; Small molecules
Mechanism of Action CXCR4 receptor antagonists; E-selectin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Osteosarcoma
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Acute myeloid leukaemia; Breast cancer; Cancer; Osteosarcoma

Most Recent Events

16 Jun 2025 GlycoMimetics has merged with Crescent Biopharma to form Crescent Biopharma
28 Mar 2024 No recent reports of development identified for preclinical development in Osteosarcoma in USA (Injection)
31 Dec 2023 Discontinued - Phase-I for Breast cancer (Late-stage disease, Metastatic disease) in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com